PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

M. Ansell, Stephen; M. Lesokhin, Alexander; Borrello, Ivan; Halwani, Ahmad; C. Scott, Emma; Gutierrez, Martin; J. Schuster, Stephen; Millenson, Michael; Cattry, Deepika; J. Freeman, Gordon; J. Rodig, Scott; Chapuy, Bjoern; H. Ligon, Azra; Zhu, Lili; F. Grosso, Joseph; Young Kim, Su; M. Timmerman, John; A. Shipp, Margaret; Armand, Philippe

doi:10.1056/nejmoa1411087

Public

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Published in New England Journal of Medicine • Dec 6, 2014

Authors:

Stephen M. Ansell

Alexander M. Lesokhin

Ivan Borrello

Abstract

BACKGROUND: Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chromosome 9p24.1 increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and promote their induction through ...

Subject

Medicine

Nivolumab

Brentuximab vedotin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!